Standout Papers
- Pembrolizumab as Second-Line Therapy for Advanced Urothelial Carcinoma (2017)
- Randomized phase III KEYNOTE-045 trial of pembrolizumab versus paclitaxel, docetaxel, or vinflunine in recurrent advanced urothelial cancer: results of >2 years of follow-up (2019)
- EV-101: A Phase I Study of Single-Agent Enfortumab Vedotin in Patients With Nectin-4–Positive Solid Tumors, Including Metastatic Urothelial Carcinoma (2020)
- Enfortumab vedotin after PD-1 or PD-L1 inhibitors in cisplatin-ineligible patients with advanced urothelial carcinoma (EV‑201): a multicentre, single-arm, phase 2 trial (2021)
Immediate Impact
5 by Nobel laureates 6 from Science/Nature 78 standout
Citing Papers
Renal cell carcinoma
2024 Standout
T-cell-engaging bispecific antibodies in cancer
2023 Standout
Works of David I. Quinn being referenced
Results of an ongoing phase 1/2a dose escalation study of HPN424, a tri-specific half-life extended PSMA-targeting T-cell engager, in patients with metastatic castration-resistant prostate cancer (mCRPC).
2021
Axitinib versus placebo as an adjuvant treatment of renal cell carcinoma: results from the phase III, randomized ATLAS trial
2018
Author Peers
| Author | Last Decade | Papers | Cites | |||
|---|---|---|---|---|---|---|
| David I. Quinn | 4686 | 5656 | 4397 | 404 | 13.7k | |
| Yoshiharu Sakai | 2937 | 5233 | 3980 | 405 | 11.5k | |
| Donato Nitti | 3185 | 5790 | 4107 | 322 | 13.4k | |
| Ezra E.W. Cohen | 5492 | 8308 | 3157 | 416 | 16.4k | |
| Hisahiro Matsubara | 4640 | 2655 | 5385 | 497 | 11.7k | |
| Jiafu Ji | 5196 | 4173 | 2964 | 505 | 14.0k | |
| Roy M. Bremnes | 4177 | 6199 | 2435 | 229 | 12.7k | |
| Mototsugu Oya | 4336 | 3151 | 3316 | 621 | 10.9k | |
| Guru Sonpavde | 4949 | 6652 | 6237 | 621 | 14.5k | |
| Dan Theodorescu | 3037 | 3515 | 3714 | 334 | 14.1k | |
| Lin Shen | 6834 | 7133 | 4049 | 473 | 14.7k |
All Works
Login with ORCID to disown or claim papers
Loading papers...